← Procept Biorobotics overview

Procept Biorobotics vs Guangzhou Wondfo Biotech: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Procept Biorobotics Corp (PRCT)

Q3 2026
▼2▲1

PRCT: Procedure Guidance Cut and Securities Class Action Weigh on Shares

  • 2026 U.S. procedure outlook slashed on legacy AQUABEAM softness Procept cut its 2026 U.S. procedure guidance to 54,000–56,000 from 60,000–64,000, citing concentrated softness in legacy AQUABEAM accounts. Q2 procedures grew 21% but missed expectations. This signals weaker demand for the older system and raises doubts about the growth trajectory, pushing the stock down.

    This is the most direct new fundamental negative for PRCT's demand outlook.

  • Securities class action alleges undisclosed discount program inflated sales Multiple law firms filed or reminded investors of a class action claiming Procept used an undisclosed discount program to pull forward handpiece sales, creating over 10,000 excess field inventory units. The lawsuit seeks damages and adds legal and reputational risk, weighing on investor sentiment.

    This is a new legal/regulatory overhang that directly pressures PRCT shares.

  • Q2 revenue beat but net loss and EBITDA loss persist Procept reported Q2 revenue of $94.5 million, up 19% year-over-year, above the consensus estimate of $92.82 million. However, the company still posted a net loss of $26.9 million and an adjusted EBITDA loss of $11.3 million, showing that profitability remains elusive despite top-line growth.

    This shows the mixed financial picture: revenue growth is positive but losses continue.

  • HYDROS upgrade cycle and positive EBITDA target offer a path forward Procept placed 65 HYDROS systems at an average selling price of about $495,000 and is accelerating upgrades of legacy AQUABEAM accounts to HYDROS. Management still expects positive adjusted EBITDA in Q4 2026 and sees the replacement cycle as a significant factor into 2027, providing a potential catalyst.

    This highlights the company's plan to offset legacy weakness and reach profitability.

July 2026
▼2▲1

PRCT: Procedure Guidance Cut and Securities Class Action Weigh on Shares

  • 2026 U.S. procedure outlook slashed on legacy AQUABEAM softness Procept cut its 2026 U.S. procedure guidance to 54,000–56,000 from 60,000–64,000, citing concentrated softness in legacy AQUABEAM accounts. Q2 procedures grew 21% but missed expectations. This signals weaker demand for the older system and raises doubts about the growth trajectory, pushing the stock down.

    This is the most direct new fundamental negative for PRCT's demand outlook.

  • Securities class action alleges undisclosed discount program inflated sales Multiple law firms filed or reminded investors of a class action claiming Procept used an undisclosed discount program to pull forward handpiece sales, creating over 10,000 excess field inventory units. The lawsuit seeks damages and adds legal and reputational risk, weighing on investor sentiment.

    This is a new legal/regulatory overhang that directly pressures PRCT shares.

  • Q2 revenue beat but net loss and EBITDA loss persist Procept reported Q2 revenue of $94.5 million, up 19% year-over-year, above the consensus estimate of $92.82 million. However, the company still posted a net loss of $26.9 million and an adjusted EBITDA loss of $11.3 million, showing that profitability remains elusive despite top-line growth.

    This shows the mixed financial picture: revenue growth is positive but losses continue.

  • HYDROS upgrade cycle and positive EBITDA target offer a path forward Procept placed 65 HYDROS systems at an average selling price of about $495,000 and is accelerating upgrades of legacy AQUABEAM accounts to HYDROS. Management still expects positive adjusted EBITDA in Q4 2026 and sees the replacement cycle as a significant factor into 2027, providing a potential catalyst.

    This highlights the company's plan to offset legacy weakness and reach profitability.

Latest
▼2▲1

PRCT: Procedure Guidance Cut and Securities Class Action Weigh on Shares

  • 2026 U.S. procedure outlook slashed on legacy AQUABEAM softness Procept cut its 2026 U.S. procedure guidance to 54,000–56,000 from 60,000–64,000, citing concentrated softness in legacy AQUABEAM accounts. Q2 procedures grew 21% but missed expectations. This signals weaker demand for the older system and raises doubts about the growth trajectory, pushing the stock down.

    This is the most direct new fundamental negative for PRCT's demand outlook.

  • Securities class action alleges undisclosed discount program inflated sales Multiple law firms filed or reminded investors of a class action claiming Procept used an undisclosed discount program to pull forward handpiece sales, creating over 10,000 excess field inventory units. The lawsuit seeks damages and adds legal and reputational risk, weighing on investor sentiment.

    This is a new legal/regulatory overhang that directly pressures PRCT shares.

  • Q2 revenue beat but net loss and EBITDA loss persist Procept reported Q2 revenue of $94.5 million, up 19% year-over-year, above the consensus estimate of $92.82 million. However, the company still posted a net loss of $26.9 million and an adjusted EBITDA loss of $11.3 million, showing that profitability remains elusive despite top-line growth.

    This shows the mixed financial picture: revenue growth is positive but losses continue.

  • HYDROS upgrade cycle and positive EBITDA target offer a path forward Procept placed 65 HYDROS systems at an average selling price of about $495,000 and is accelerating upgrades of legacy AQUABEAM accounts to HYDROS. Management still expects positive adjusted EBITDA in Q4 2026 and sees the replacement cycle as a significant factor into 2027, providing a potential catalyst.

    This highlights the company's plan to offset legacy weakness and reach profitability.

Guangzhou Wondfo Biotech Co Ltd (300482.CS)

Q3 2026
▲3▼1

Wondfo's first-half profit and cash recovery offset a decade-first annual loss

  • First loss in a decade as policy squeezes demand and prices Wondfo's 2025 revenue fell 31.91% and it posted its first loss since listing, hit by centralized procurement and DRG/DIP payment rules that cut test volumes and prices. The stock hit a new low, down about 72% from its peak, showing how badly policy pressure hurt the core testing business.

    Explains the main force behind the stock's slump and why investors are worried.

  • Buyback and controlling-shareholder purchases signal insider confidence The company approved a 30-60 million yuan buyback, and controlling shareholder Wang Jihua bought 1.156 million shares for about 20 million yuan, completing her 20-40 million yuan plan. Insiders putting real money in suggests they see the shares as undervalued, which can support the price.

    Shows concrete capital actions that counter the negative news and support the stock.

  • First-half profit and cash flow swing back to positive Wondfo reported first-half 2026 revenue of 1.039 billion yuan and net profit of 123 million yuan, with operating cash flow turning from a 56.31 million yuan outflow to a 423.99 million yuan inflow. Gross margin edged up, and overseas molecular diagnostics revenue jumped 228%, suggesting the worst may be passing.

    This is the key new evidence that the business is recovering, directly answering why the stock may be moving.

  • Seven new chemiluminescence registrations widen product range Wondfo received seven chemiluminescence device registration certificates covering liver, islet and heart tests. These add to its product lineup and support its push into the larger in-vitro diagnostics market, though the company says the revenue impact cannot yet be predicted.

    Shows new product momentum that could drive future growth, a fresh positive for the stock.

August 2026
▲3▼1

Wondfo's first-half profit and cash recovery offset a decade-first annual loss

  • First loss in a decade as policy squeezes demand and prices Wondfo's 2025 revenue fell 31.91% and it posted its first loss since listing, hit by centralized procurement and DRG/DIP payment rules that cut test volumes and prices. The stock hit a new low, down about 72% from its peak, showing how badly policy pressure hurt the core testing business.

    Explains the main force behind the stock's slump and why investors are worried.

  • Buyback and controlling-shareholder purchases signal insider confidence The company approved a 30-60 million yuan buyback, and controlling shareholder Wang Jihua bought 1.156 million shares for about 20 million yuan, completing her 20-40 million yuan plan. Insiders putting real money in suggests they see the shares as undervalued, which can support the price.

    Shows concrete capital actions that counter the negative news and support the stock.

  • First-half profit and cash flow swing back to positive Wondfo reported first-half 2026 revenue of 1.039 billion yuan and net profit of 123 million yuan, with operating cash flow turning from a 56.31 million yuan outflow to a 423.99 million yuan inflow. Gross margin edged up, and overseas molecular diagnostics revenue jumped 228%, suggesting the worst may be passing.

    This is the key new evidence that the business is recovering, directly answering why the stock may be moving.

  • Seven new chemiluminescence registrations widen product range Wondfo received seven chemiluminescence device registration certificates covering liver, islet and heart tests. These add to its product lineup and support its push into the larger in-vitro diagnostics market, though the company says the revenue impact cannot yet be predicted.

    Shows new product momentum that could drive future growth, a fresh positive for the stock.

Latest
▲3▼1

Wondfo's first-half profit and cash recovery offset a decade-first annual loss

  • First loss in a decade as policy squeezes demand and prices Wondfo's 2025 revenue fell 31.91% and it posted its first loss since listing, hit by centralized procurement and DRG/DIP payment rules that cut test volumes and prices. The stock hit a new low, down about 72% from its peak, showing how badly policy pressure hurt the core testing business.

    Explains the main force behind the stock's slump and why investors are worried.

  • Buyback and controlling-shareholder purchases signal insider confidence The company approved a 30-60 million yuan buyback, and controlling shareholder Wang Jihua bought 1.156 million shares for about 20 million yuan, completing her 20-40 million yuan plan. Insiders putting real money in suggests they see the shares as undervalued, which can support the price.

    Shows concrete capital actions that counter the negative news and support the stock.

  • First-half profit and cash flow swing back to positive Wondfo reported first-half 2026 revenue of 1.039 billion yuan and net profit of 123 million yuan, with operating cash flow turning from a 56.31 million yuan outflow to a 423.99 million yuan inflow. Gross margin edged up, and overseas molecular diagnostics revenue jumped 228%, suggesting the worst may be passing.

    This is the key new evidence that the business is recovering, directly answering why the stock may be moving.

  • Seven new chemiluminescence registrations widen product range Wondfo received seven chemiluminescence device registration certificates covering liver, islet and heart tests. These add to its product lineup and support its push into the larger in-vitro diagnostics market, though the company says the revenue impact cannot yet be predicted.

    Shows new product momentum that could drive future growth, a fresh positive for the stock.